Zhongsheng Beikong Biotechnology Co., Ltd. (“Zhongsheng Beikong” or the “Company”) is the leading supplier of in vitro diagnostic (“in vitro diagnosis”) reagents in the People's Republic of China (“China”). The Company and its subsidiaries (collectively, the “Group”) are mainly engaged in R&D, production, sales and distribution of in vitro diagnostic reagent products, and provide high-quality and reliable disease detection reagent products to hospitals and other medical institutions. The company's main shareholder has a strong background. The largest shareholder, Beijing Pusai Asset Management Co., Ltd., is a wholly-owned subsidiary of the Institute of Biophysics (“Institute of Biophysics”) of the Chinese Academy of Sciences (“Chinese Academy of Sciences”). The Institute of Biophysics is the most authoritative research institution in life science in China. The Group's brand “Zhongsheng” is famous in the industry. “Zhongsheng” was awarded the “Beijing Famous Brand Product” award in 2002, the “No. 1 Brand for Customer Satisfaction Quality and Reputation in the Chinese Diagnostic Reagent Market” award in 2005, and the title of “Beijing Famous Trademark”, which is widely recognized by market users and the medical community. The Group has adopted a marketing model combining direct sales and distributors, and has established an efficient, stable marketing network covering more than 600 distributors in more than 30 provinces, municipalities and autonomous regions across the country. The Group's diagnostic reagent products are widely sold in domestic hospitals and medical institutions. In addition, the management of the Group includes a number of university professors and PhDs, and has continuously strengthened the Group's overall competitiveness based on the business policy of “putting people first, advocating innovation, quality first, pursuing perfection, honest labor and legal management”. Many of these management members have been engaged in research work at the Institute of Biophysics. Their strong scientific research background and ambitions have laid a good scientific research foundation for Zhongsheng Beijing Holdings, and also helped the long-term development of the Group's business. The Company's H shares have been listed on GEM since February 27, 2006.
No Data
No Data